Pathology and pathobiology of pulmonary hypertension: current insights and future directions
European Respiratory Journal · 2024-10 · 64 (4) · 2401095
DOI: 10.1183/13993003.01095-2024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Respiratory Journal, online erschienen am 29.08.2024. Verfasst von Christophe Guignabert und 9 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, Franc…. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Vascular Remodeling. Die Arbeit wurde bisher 184-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
In recent years, major advances have been made in the understanding of the cellular and molecular mechanisms driving pulmonary vascular remodelling in various forms of pulmonary hypertension, including pulmonary arterial hypertension, pulmonary hypertension associated with left heart disease, pulmonary hypertension associated with chronic lung disease and hypoxia, and chronic thromboembolic pulmonary hypertension. However, the survival rates for these different forms of pulmonary hypertension remain unsatisfactory, underscoring the crucial need to more effectively translate innovative scientific knowledge into healthcare interventions. In these proceedings of the 7th World Symposium on Pulmonary Hypertension, we delve into recent developments in the field of pathology and pathophysiology, prioritising them while questioning their relevance to different subsets of pulmonary hypertension. In addition, we explore how the latest omics and other technological advances can help us better and more rapidly understand the myriad basic mechanisms contributing to the initiation and progression of pulmonary vascular remodelling. Finally, we discuss strategies aimed at improving patient care, optimising drug development, and providing essential support to advance research in this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Université Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France.
- INSERM UMR_S 999, HPPIT, Le Kremlin-Bicêtre, France.
- Department of Pulmonary Medicine, Amsterdam UMC, VU University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
- Pulmonary Hypertension research group, Centre de Recherche de l'Institut de Cardiologie et de Pneumologie de Québec, Quebec City, QC, Canada.
- Department of Medicine, Université Laval, Quebec City, QC, Canada.
- Department of Pathology, University Hospital Giessen/Marburg, Giessen, Germany.
ORCID-Profile: Christophe Guignabert, Peter Dorfmüller, Andrea J Olschewski, Soni Pullamsetti, Ralph T Schermuly, Marc Humbert
Förderung
- NHLBI NIH HHS
Zitieren
APA
Guignabert, C., Aman, J., Bonnet, S., Dorfmüller, P., Olschewski, A. J., Pullamsetti, S., Rabinovitch, M., Schermuly, R. T., Humbert, M., & Stenmark, K. R. (2024). Pathology and pathobiology of pulmonary hypertension: current insights and future directions. European Respiratory Journal, 64(4), 2401095. https://doi.org/10.1183/13993003.01095-2024
Vancouver
Guignabert C, Aman J, Bonnet S, Dorfmüller P, Olschewski AJ, Pullamsetti S, et al. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. European Respiratory Journal. 2024;64(4):2401095. doi:10.1183/13993003.01095-2024
BibTeX
@article{Guignabert2024,
author = {Guignabert, Christophe and Aman, Jurjan and Bonnet, Sébastien and Dorfmüller, Peter and Olschewski, Andrea J and Pullamsetti, Soni and Rabinovitch, Marlene and Schermuly, Ralph T and Humbert, Marc and Stenmark, Kurt R},
title = {Pathology and pathobiology of pulmonary hypertension: current insights and future directions},
journal = {European Respiratory Journal},
year = {2024},
volume = {64},
number = {4},
pages = {2401095},
doi = {10.1183/13993003.01095-2024}
}
EUVIMED